Overview
"Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial
Status:
Terminated
Terminated
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Dying patients are often unable to clear secretions from their large airways, resulting in noisy breathing usually described as "death rattle." While there is no evidence that patients find this condition disturbing, the noises may be disturbing to the patient's visitors and caregivers who may fear that the patient is choking to death. In Israel none of the pharmaceutical drugs listed in the literature exist. Thus, Atropine drops which have been noted in the literature as being used, though according to our knowledge no evidence of clinical trials using sublingual Atropine were conducted. The study is designed as a randomly controlled, double blind crossover trial. The patient will serve as control for himself, as crossover between placebo and drug (randomly chosen) will take place. The administrator of the drug will be blinded to the medication, each time randomly beginning with a different drug (placebo or Atropine). We will evaluate Atropine Sulphate 1% ophthalmic drops effect on 33 patients using a noise score scale of 0-3. Noise scores will be taken at the start; 30 min after drug/placebo administration and every hour thereafter. After 4-hours crossover will take place and evaluation will follow the same protocol.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Soroka University Medical CenterCollaborator:
Ben-Gurion University of the NegevTreatments:
Atropine
Ophthalmic Solutions
Criteria
Inclusion Criteria:- : Patients belonging to Home Palliative Care Unit of Clalit Health Services - Southern
District, and the Oncology Department of Soroka University Medical Center and
suffering from "death rattle" will be recruited for the study.
Exclusion Criteria:
-